VJHemOnc is committed to improving our service to you

ASH 2019 | Venetoclax with mini-hyper-CVD for ALL

VJHemOnc is committed to improving our service to you

Nitin Jain

Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results from the multicenter phase I study combining venetoclax with mini-hyperfractionated cyclophosphamide, vincristine and dexamethasone (mini-hyper-CVD) in older adults with untreated or relapsed/refractory acute lymphoblastic leukemia (ALL). Although the complete remission and MRD rates were exceptionally high, longer follow-up is needed. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter